Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis

详细信息    查看全文

• 作者：Mark S. Freedman^a ; ^{mfreedman@toh.ca} ; Xavier Montalban^b ; Aaron E. Miller^c ; Catherine Dive-Pouletty^d ; Steven Hass^e ; Karthinathan Thangavelu^e ; Thomas P. Leist^f
• 关键词：AE ; adverse event ; ARR ; annualized relapse rate ; DMF ; dimethyl fumarate ; DMT ; disease-modifying therapy ; EDSS ; Expanded Disability Status Scale ; FS ; Functional System ; IV ; intravenous ; MS ; multiple sclerosis ; NNH ; number needed to harm ; NNT ; number needed to treat
• 刊名：Multiple Sclerosis and Related Disorders
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：10
• 期：Complete
• 页码：204-212
• 全文大小：188 K
• 卷排序：10

文摘

NNT can provide an additional measure of comparative efficacy of DMTs across trials [85/85]. NNTs were similar across key clinical outcomes for teriflunomide, DMF &$2 fingolimod [84/85]. Teriflunomide had a lower NNT to prevent some severe relapses vs DMF or fingolimod [84/85]. Only teriflunomide showed consistently low NNTs to prevent disability progression [83/85]. These NNT data have clinical relevance and may help to inform treatment decisions [83/85].